UBS Group’s CME Group CME Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $28.3M | Sell |
95,800
-14,200
| -13% | -$4.22M | ﹤0.01% | 2219 |
|
|
2025
Q4 | $30M | Buy |
110,000
+2,800
| +3% | +$761K | ﹤0.01% | 2172 |
|
|
2025
Q3 | $29M | Buy |
107,200
+7,500
| +8% | +$2.04M | ﹤0.01% | 2167 |
|
|
2025
Q2 | $27.5M | Buy |
99,700
+20,000
| +25% | +$5.44M | ﹤0.01% | 2055 |
|
|
2025
Q1 | $21.1M | Buy |
79,700
+77,100
| +2,965% | +$19M | ﹤0.01% | 2264 |
|
|
2024
Q4 | $604K | Sell |
2,600
-19,900
| -88% | -$4.58M | ﹤0.01% | 5708 |
|
|
2024
Q3 | $4.96M | Sell |
22,500
-2,400
| -10% | -$497K | ﹤0.01% | 3083 |
|
|
2024
Q2 | $4.9M | Sell |
24,900
-101,600
| -80% | -$21M | ﹤0.01% | 2893 |
|
|
2024
Q1 | $27.2M | Sell |
126,500
-84,100
| -40% | -$17.7M | 0.01% | 1456 |
|
|
2023
Q4 | $44.4M | Sell |
210,600
-89,000
| -30% | -$19M | 0.01% | 1049 |
|
|
2023
Q3 | $60M | Buy |
299,600
+47,800
| +19% | +$9.5M | 0.02% | 734 |
|
|
2023
Q2 | $46.7M | Buy |
251,800
+23,200
| +10% | +$4.29M | 0.02% | 873 |
|
|
2023
Q1 | $43.8M | Buy |
228,600
+129,800
| +131% | +$23.5M | 0.02% | 853 |
|
|
2022
Q4 | $16.6M | Buy |
98,800
+24,800
| +34% | +$4.31M | 0.01% | 1558 |
|
|
2022
Q3 | $13.1M | Sell |
74,000
-200
| -0.3% | -$39.5K | 0.01% | 1568 |
|
|
2022
Q2 | $15.2M | Sell |
74,200
-22,100
| -23% | -$4.68M | 0.01% | 1515 |
|
|
2022
Q1 | $22.9M | Buy |
96,300
+24,700
| +34% | +$5.8M | 0.01% | 1325 |
|
|
2021
Q4 | $16.4M | Sell |
71,600
-55,253
| -44% | -$12.2M | ﹤0.01% | 1719 |
|
|
2021
Q3 | $24.5M | Hold |
126,853
| – | – | 0.01% | 1344 |
|
|
2021
Q2 | $27M | Buy |
126,853
+19,339
| +18% | +$4.08M | 0.01% | 1255 |
|
|
2021
Q1 | $22M | Buy |
+107,514
| New | +$21.2M | 0.01% | 1380 |
|
|
2020
Q3 | – | Sell |
-41,800
| Closed | -$6.79M | – | 8025 |
|
|
2020
Q2 | $6.79M | Buy |
+41,800
| New | +$7.49M | ﹤0.01% | 1813 |
|
|
2019
Q3 | – | Sell |
-24,600
| Closed | -$4.78M | – | 8018 |
|
|
2019
Q2 | $4.78M | Sell |
24,600
-19,900
| -45% | -$3.67M | ﹤0.01% | 2365 |
|
|
2019
Q1 | $7.32M | Buy |
+44,500
| New | +$7.87M | ﹤0.01% | 1914 |
|
|
2017
Q4 | – | Sell |
-5,200
| Closed | -$706K | – | 7859 |
|
|
2017
Q3 | $706K | Buy |
+5,200
| New | +$657K | ﹤0.01% | 3969 |
|
|
2015
Q2 | – | Sell |
-3,900
| Closed | -$369K | – | 8520 |
|
|
2015
Q1 | $369K | Sell |
3,900
-3,500
| -47% | -$324K | ﹤0.01% | 4386 |
|
|
2014
Q4 | $656K | Buy |
+7,400
| New | +$627K | ﹤0.01% | 3942 |
|
Other funds holding CME
VCM
VPM
UBS Group's CME Position: Q1 2026 in Review
UBS Group increased its CME Group (CME) stake by 7.5% in Q1 2026, buying an estimated $41.8M and bringing the position to 2,022,656 shares worth $597M. The position accounts for 0.09% of the portfolio, ranked #224.
UBS Group first reported a position in CME in Q4 2014 and has held it in 46 quarters since. The position peaked at $805M in Q2 2025. 1,790 funds tracked by Wall St. Rank hold CME as of Q1 2026.
- UBS Group held 2,022,656 shares of CME Group worth $597M as of Q1 2026.
- UBS Group bought 140,840 CME Group shares in Q1 2026, an estimated $41.8M.
- CME Group made up 0.09% of UBS Group's portfolio in Q1 2026, its #224 holding.
- UBS Group first reported a position in CME Group in Q4 2014 and has held it in 46 quarters since.
- UBS Group's CME Group position peaked at $805M in Q2 2025.
- 1,790 funds tracked by Wall St. Rank held CME Group as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.